Loading…
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $45M | $-7M | $-10M | $-12M | -27.5% | -6.1% | 2134.2% |
| 2024 | $48M | $5M | $-0M | $27M | 7.4% | 123.7% | -97.3% |
| 2023 | $21M | $-12M | $-16M | $-17M | 138.1% | 1284.5% | -32.3% |
| 2022 | $2M | $-23M | $-24M | $-18M | 923.1% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 1.54 | 21.25 | 47.54 | 44.64 |
| Operating Revenue | - | 1.54 | 21.25 | 47.54 | 44.64 |
| Cost Of Revenue | - | 0.09 | 1.26 | 3.18 | 3.76 |
| Gross Profit | - | 1.45 | 19.99 | 44.35 | 40.88 |
| Operating Expense | - | 24.19 | 33.05 | 41.88 | 47.22 |
| Research And Development | - | 3.53 | 0.06 | 0.31 | 0.25 |
| Selling General And Administration | - | 20.51 | 32.71 | 41.48 | 46.91 |
| Total Expenses | - | 24.27 | 34.31 | 45.06 | 50.99 |
| Operating Income | - | -22.74 | -13.06 | 2.48 | -6.35 |
| Total Operating Income As Reported | - | -22.59 | -12.77 | 2.57 | -6.28 |
| EBITDA | - | -22.59 | -12.36 | 4.80 | -7.45 |
| Normalized EBITDA | - | -22.39 | -12.33 | 4.96 | -5.46 |
| EBIT | - | -22.74 | -12.65 | 4 | -7.56 |
| Interest Income | - | 0.20 | 0.44 | 1.68 | 0.79 |
| Interest Expense | - | 0.98 | 3.39 | 4.07 | 2.08 |
| Net Interest Income | - | -0.78 | -2.95 | -2.39 | -1.29 |
| Other Income Expense | - | -0.19 | -0.03 | -0.16 | -2 |
| Interest Income Non Operating | - | 0.20 | 0.44 | 1.68 | 0.79 |
| Interest Expense Non Operating | - | 0.98 | 3.39 | 4.07 | 2.08 |
| Net Non Operating Interest Income Expense | - | -0.78 | -2.95 | -2.39 | -1.29 |
| Pretax Income | - | -23.71 | -16.05 | -0.07 | -9.64 |
| Tax Provision | - | - | 0 | 0.36 | 0.11 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | -0.03 | -0.42 |
| Net Income Continuous Operations | - | -23.71 | -16.05 | -0.44 | -9.74 |
| Net Income From Continuing And Discontinued Operation | - | -23.71 | -16.05 | -0.44 | -9.74 |
| Net Income From Continuing Operation Net Minority Interest | - | -23.71 | -16.05 | -0.44 | -9.74 |
| Net Income | - | -23.71 | -16.05 | -0.44 | -9.74 |
| Net Income Common Stockholders | - | -23.71 | -16.05 | -0.44 | -9.74 |
| Net Income Including Noncontrolling Interests | - | -23.71 | -16.05 | -0.44 | -9.74 |
| Normalized Income | - | -23.52 | -16.01 | -0.31 | -8.16 |
| Diluted NI Availto Com Stockholders | - | -23.71 | -16.05 | -0.44 | -9.74 |
| Basic Average Shares | - | 26.28 | 26.57 | 27.29 | 28.58 |
| Diluted Average Shares | - | 26.28 | 26.57 | 27.29 | 28.58 |
| Reconciled Depreciation | - | 0.15 | 0 | 0.80 | 0.10 |
| Reconciled Cost Of Revenue | - | 0.09 | 1.55 | 2.47 | 3.72 |
| Total Unusual Items | - | -0.19 | -0.03 | -0.16 | -2 |
| Total Unusual Items Excluding Goodwill | - | -0.19 | -0.03 | -0.16 | -2 |
| Special Income Charges | - | - | - | 0 | -2.02 |
| Other Special Charges | - | - | - | - | 2.02 |
| Gain On Sale Of Security | - | -0.19 | -0.03 | -0.16 | 0.03 |
| Depreciation Amortization Depletion Income Statement | - | 0.15 | 0.29 | 0.09 | 0.06 |
| Depreciation And Amortization In Income Statement | - | 0.15 | 0.29 | 0.09 | 0.06 |
| General And Administrative Expense | - | 17.72 | 20.58 | 23.05 | 28.29 |
| Other Gand A | - | 17.72 | 20.58 | 23.05 | 28.29 |
| Total Other Finance Cost | 0.02 | 0.15 | 0.29 | 0.09 | - |
| Selling And Marketing Expense | - | 2.78 | 12.12 | 18.43 | 18.62 |
| Amortization | - | 0.15 | 0.29 | 0.09 | 0.06 |
| Amortization Of Intangibles Income Statement | - | 0.15 | 0.29 | 0.09 | 0.06 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc.this co. | FENC | $318M | -32.67 | 8.97 | -27.5% | -37.76 |
| 908 Devices Inc. | MASS | $334M | 17.11 | 2.32 | 13.6% | -12.61 |
| Abeona Therapeutics Inc. | ABEO | $332M | 4.66 | 2.08 | 44.7% | 3.54 |
| Humacyte, Inc. | HUMA | $331M | -8.10 | 106.40 | -1313.4% | -15.52 |
| Organogenesis Holdings Inc. | ORGO | $319M |
| - |
| - |
| - |
| - |
| - |
| - |
| 8.62 |
| 1.06 |
| 12.3% |
| 3.71 |
| Rocket Pharmaceuticals, Inc. | RCKT | $319M | -1.43 | 1.15 | -80.5% | -1.27 |
| SIGA Technologies, Inc. | SIGA | $318M | 13.65 | 1.60 | 11.7% | 6.73 |
| DiaMedica Therapeutics Inc. | DMAC | $315M | - | 5.61 | -58.4% | - |
| Electromed, Inc. | ELMD | $304M | 40.34 | 7.04 | 17.4% | 26.66 |
| Peer Median | - | 8.62 | 2.20 | 12.0% | 3.54 | |